Aktienanalyse zu Inmode Ltd (INMD)INMDInmode Ltd

Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures. It operates in the Healthcare sector (ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS industry).

InMode Ltd is currently priced at $13.97, which is below the analyst price target of $17, indicating potential upside. However, the RSI is at 30.293, suggesting the stock is oversold, and the company has experienced a 10.73% decline over the past year. The main risk is the recent downgrade in analyst ratings and the uncertainty surrounding the acquisition bid, which could affect stock performance.